Forest/Almirall’s Aclidinium Disappoints In Phase III COPD Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Bronchodilatory effect of aclidinium was statistically significant compared to placebo, but lower than seen in previous studies.
You may also be interested in...
Positive COPD Data Allows Forest To File For Approval of Eklira in 2011
Forest Laboratories and Spain's Almirall report positive late-stage data for their COPD drug, paving the way for 2011 regulatory filings in the U.S. and EU.
Positive COPD Data Allows Forest To File For Approval of Eklira in 2011
Forest Laboratories and Spain's Almirall report positive late-stage data for their COPD drug, paving the way for 2011 regulatory filings in the U.S. and EU.
For Forest, No Single Silver Bullet But Many Opportunities
There is no quick fix to guide Forest Laboratories through 2012, when its best-seller, the antidepressant Lexapro, goes off patent. But management thinks it will have enough patches in place by then to compensate for lost revenues and avert disaster